Faculty profile

Paul Wheatley-Price

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Ottawa

Paul Wheatley-Price

Assistant Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
54 publications in the last five years, latest in 2026.
Senior (last) author on 19 recent papers, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,043

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors
Journal of the National Cancer Institute · 2026
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts
Lung Cancer · 2026
Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era
Current Oncology · 2026 · senior author

All 93 publications

93 publications.

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Melosky B, Juergens RA, Chu QSC, Cheema P, Snow S, Leighl NB, Blais N, Ionescu DN, McLeod D, Tsao M-S

Journal of the National Cancer Institute20265 citations

DOI: 10.1093/jnci/djag008

Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts

Ko JJ, Blais N, Brade A, Clelland C, Juergens R, Liu G, Navani V, Snow S, Wheatley-Price P, Melosky B

Lung Cancer2026

DOI: 10.1016/j.lungcan.2026.109455

Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era

Theriau CF, Li Y, Akurang D, Moore SM, Juergens RA, Leighl NB, Wheatley-Price P

Current Oncology2026Senior author

DOI: 10.3390/curroncol33050277

Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer.

Gauthier SN, Wheatley-Price P, Stewart DJ, Brule S, Ney M, Nicholas G, Moore SM

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33070388 PMID: 42505190

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Monzon JG, Karachiwala H, Walker J, Goel R, Wheatley-Price P, Asmis TR, Navani V, Tang PA, Vickers MM

European journal of cancer (Oxford, England : 1990)2026

DOI: 10.1016/j.ejca.2026.116738 PMID: 41997036

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

Monzon JG, Karachiwala H, Walker J, Goel R, Wheatley-Price P, Asmis TR, Navani V, Tang PA, Vickers MM

European journal of cancer (Oxford, England : 1990)2026

DOI: 10.1016/j.ejca.2026.116709 PMID: 41935492

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Wheatley Price P, Ismaila N, Calles Blanco A, Cetnar J, Conneran T, Desai PA, Durm G, Horinouchi H, Khurshid H, Kulkarni S, Marrone KA, Perdrizet K, Bazhenova L

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026First author

DOI: 10.1200/jco-26-01958 PMID: 42607282

Prophylactic Cranial Irradiation and Survival in Limited-Stage SCLC: A Multicenter Real-World Analysis From the Canadian SCLC Database (CASCADE).

Lone AH, Ye XY, Zhan LJ, Yang H, Smyth V, Abdelaziz RH, Snow S, Genta S, Kuruvilla S, Agulnik J, Navani V, Ho C, Dawe D, Wheatley-Price P, Moore S, Liu G, Lok BH

JTO clinical and research reports2026

DOI: 10.1016/j.jtocrr.2026.101030 PMID: 42502471

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Puri S, Ismaila N, Azar IH, Freeman-Daily J, Furuya N, Kuruvilla S, Roof L, Velazquez AI, Wang Y, Wheatley Price P, Leighl NB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026

DOI: 10.1200/jco-26-01479 PMID: 42372216

The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.

Phillips WJ, Leong R, Yeung B, Al Lawati A, Camidge DR, Lo B, Wheatley-Price P

Current oncology (Toronto, Ont.)2026Senior author

DOI: 10.3390/curroncol33080439 PMID: 42645345

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Paul Wheatley-Price

Research

Latest papers

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts

Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era

Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer.

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Prophylactic Cranial Irradiation and Survival in Limited-Stage SCLC: A Multicenter Real-World Analysis From the Canadian SCLC Database (CASCADE).

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.

Frequent collaborators

Geoffrey Liu

Rosalyn Juergens

Ming-Sound Tsao

Adrian Sacher

Mark Clemons

Glenwood Goss

John Goffin

Bryan Lo

Lesley Seymour

Tim Aubry

Sophie Lebel

Rinat Nissim

Rakesh Goel

Courtney Heather Coschi

Brian Hutton

Gerald Batist

Gerald Batist

Michael Yan

Robert MacRae

Paul Arora

Christopher Pease

Kimberly McMillan

Eitan Amir